By Louis Blankemeier
In October 2024, my co-founders and I embarked on a mission to translate our Ph.D. research into tangible healthcare solutions. We developed AI models capable of interpreting medical images such as X-rays and CT scans across thousands of potential diagnoses, creating comprehensive radiology reports that mirror radiologists’ clinical reasoning. This represented a major leap at a time when AI in radiology only flagged a few specific conditions.

Less than a year later, we faced a critical decision: continue raising venture capital and advance independently or accept an acquisition from Radiology Partners, the largest radiology practice worldwide. Contrary to the tech norm emphasizing independence, we chose collaboration to significantly boost our chances of transforming healthcare access.

Clinical AI faces complex regulatory hurdles, long sales cycles, and challenging market dynamics that favor well-established players. Joining forces with a major industry player offered resources, extensive data, and clinical integration required to develop reliable, scalable models. Research-scale successes do not guarantee clinical readiness; real-world radiology demands massive, diverse datasets and continuous performance monitoring to handle complex, high-stakes cases.

Moreover, sustainable success in healthcare AI hinges on rigorous evidence from large-scale implementation across diverse populations and environments, not small pilots. Partnering with Radiology Partners provided the infrastructure and credibility essential for trust and adoption, accelerating our mission to expand access to high-quality healthcare worldwide.

Louis Blankemeier is CEO and co-founder of Cognita, part of Radiology Partners. His work bridges AI research and clinical application, driven to improve healthcare accessibility through technology.

Florence Nightingale is often remembered as a compassionate nurse, yet her pioneering work transformed healthcare through innovation. Her strategies—powerful data communication, clear public guidance, and formalized training—reshaped nursing and hospital sanitation practices, leaving lessons relevant for today’s leaders.

Born in 1812 in Italy, Nightingale defied societal norms to pursue nursing. During the Crimean War, she and her team improved hospital conditions amidst dire circumstances, using data-driven visuals, like her famous 1858 polar area chart, to advocate for sanitation reforms. She also authored Notes on Nursing, providing accessible, practical advice for caregivers, and led the establishment of the first formal nursing school, professionalizing training and broadening healthcare access.

Nightingale’s impact extended beyond immediate reforms; her work influenced public health policies that increased life expectancy in the UK by nearly 40% over five decades. Her legacy underscores the power of doing things differently, using simple tools effectively, and nurturing disruptive innovation through curiosity, collaboration, and persistence.

The path from a lab hypothesis to a commercial medicine is long and costly, often taking 10 to 15 years and massive investment. This journey is complicated by fragmented workflows that force scientists to juggle multiple databases, software, and experimental setups manually. OpenAI's new AI model, GPT-Rosalind, aims to revolutionize this process by serving as a specialized assistant for life sciences research. Named after Rosalind Franklin, a trailblazing chemist in DNA discovery, GPT-Rosalind is designed to accelerate hypothesis synthesis, experiment planning, and data integration, optimized for genomics, protein engineering, and chemistry.

Unlike previous general-purpose AI, GPT-Rosalind offers deep domain expertise, demonstrated by its top-tier performance on bioinformatics and molecular cloning tasks. Its sequence-to-function prediction skills even ranked in the 95th percentile among human experts. To streamline research, OpenAI also released a Life Sciences research plugin for Codex on GitHub, connecting researchers to over 50 multi-omics databases, enabling automated, complex workflows in biochemistry and genetics with greater efficiency.

Access to GPT-Rosalind is limited to qualified US enterprise customers under strict governance and security controls, ensuring the technology is used responsibly for public benefit. Early industry feedback from leaders at Amgen, NVIDIA, Moderna, and the Allen Institute highlights the model's potential to compress research timelines and enhance reproducibility. Building on successes like a 40% cost reduction in protein production via AI collaboration, OpenAI envisions GPT-Rosalind as a key partner advancing biological and chemical discovery.

STORM Therapeutics, a clinical-stage biotech firm based in Cambridge, has raised $56 million in a Series C funding round led by existing investors such as Pfizer Ventures and M Ventures. Their lead compound, STC-15, is the first RNA-modifying enzyme inhibitor to enter human trials, demonstrating durable tumor regression in Phase 1 across various sarcoma subtypes. The funds will support ongoing development targeting RNA modifications in cancer therapy.

Social media has dramatically accelerated the pace at which beauty trends influence real-world aesthetic treatments, often pushing consumers to make quick and sometimes uninformed decisions. This disconnect arises because aesthetic inspiration is collective and social, but the results are personal and vary greatly based on individual biology. AI is bridging this gap by providing precise, personalized consultations that predict actual outcomes and help patients align expectations with their unique facial characteristics. Technologies like AI Skin Analysis offer dermatologist-validated diagnostics that personalize skin health assessments, transforming patient education from a clinical luxury into a standard practice. AI visualization tools empower patients to see realistic simulations of treatments like Botox and filler, fostering confidence and trust. Practitioners report increased patient satisfaction, repeat visits, and higher spending when integrating these AI tools. Furthermore, democratized access to AI APIs allows brands and clinics of all sizes to provide personalized skin education, enhancing customer engagement and decision-making. This technological shift marks an inflection point where practitioners and brands can build lasting consumer trust through data-driven, personalized care rather than generic social media trends.

AI companies often make bold promises about revolutionizing healthcare, claiming breakthroughs in scientific discovery and medicine development. Yet, the true measure of success is whether these AI technologies have been proven to work in humans, creating life-saving treatments. Unfortunately, most have yet to meet this standard. Real progress in healthcare demands extensive clinical trials, rigorous testing, and years of effort. Leading AI healthcare companies like Insilico Medicine, Recursion, and Owkin are closing the gap by advancing AI-driven discoveries through clinical trials and training AI models on authentic patient data. This approach fosters a continuous improvement cycle where AI performance is refined through real-world feedback, ultimately benefiting patients. While the excitement around AI’s potential is justified, only the AI that withstands the challenges of clinical reality will truly transform medicine.

OpenAI has introduced the first model in its Life Science series, aiming to challenge Google’s AlphaFold in advancing life sciences research. This new AI model is designed to support breakthroughs in the biology and healthcare sectors by providing innovative tools for scientific discovery.

Eindhoven-based neurotechnology firm ONWARD Medical has successfully raised €40.6 million to finance its pivotal Empower BP trial, investigating the efficacy of its implantable ARC-IM® system for managing blood pressure instability following spinal cord injury. The funding will also support the broader commercial expansion of its cleared ARC-EX® external therapy system. With this investment, the company's cash runway is expected to extend through Q1 2028.

AIM Centre is extending its reach beyond its Sligo headquarters by establishing a new base in Galway, aiming to tap into the growing medtech and life sciences clusters in the west of Ireland.

New York-based startup Coral has developed AI technology capable of reading handwritten fax forms, handling prior authorizations, and completing patient intake processes in under five minutes — all without requiring healthcare providers to alter their current workflows. Within its first year, Coral has generated several million dollars in revenue and aims to quadruple its growth by the end of 2026.